Arno Therapeutics Completes $30.7 Million Financing, Recapitalization and 1-for-8 Reverse Stock Split
October 30, 2013 08:00 ET
|
Arno Therapeutics Inc.
– All Outstanding Convertible Debentures Converted into Common Stock –
– Funds to be Used for Continued Clinical Development of Lead Candidate, Onapristone –...
Arno Therapeutics Data Supports Further Evaluation of Onapristone in Prostate Cancer
October 29, 2013 17:00 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Oct. 29, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
Arno Therapeutics to Present Data Validating Target Biomarker at European Cancer Congress 2013
September 28, 2013 08:00 ET
|
Arno Therapeutics Inc.
Poster Session: Diagnostics/Biomarkers, Hall 4
Abstract #1001; Poster #258
Abstract #1002; Poster #274
- Underscores role of anti-progestins -
- Supports further evaluation of onapristone and...
Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors
September 09, 2013 08:00 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Sept. 9, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
Arno Therapeutics Initiates Pharmacokinetic Study for Onapristone Following Regulatory Acceptance
August 21, 2013 09:06 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Aug. 21, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
Arno Therapeutics to Collaborate With Veridex on Development of Diagnostic Test
June 03, 2013 08:00 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., June 3, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced...
Arno Therapeutics to Collaborate With Clarient for Development of Diagnostic Test
May 10, 2013 08:00 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., May 10, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced...
Arno Therapeutics Reports Activated Progesterone Receptors Predictive of Response to Onapristone
April 08, 2013 13:00 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., April 8, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
Arno Therapeutics Engages The Ruth Group for Investor Relations and Public Relations Counsel
March 19, 2013 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., March 19, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCBB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...